A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in Myelofibrosis

Sponsor
Qilu Hospital of Shandong University
Study ID
NCT05447260
Phase
PHASE4
Status
Unknown

Conditions

  • Myelofibrosis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a multi-center, prospective, single-arm study to assess safety and efficacy of Ruxolitinib in myelofibrosis (MF) based on a new prognostic stratification.

Key Dates

Start date
Jun 10, 2022
Status verified
Jul 2022
Primary completion
Dec 10, 2022
Completion
Dec 10, 2023

Study Design

Enrollment
87 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Ruxolitinib

Primary Outcome Measure

The proportion of patients with a ≥35% reduction in palpable spleen volume from baseline. [ Time Frame: From Week 0 through Week 24 ]

Central Contacts

Related Studies